13 assets in Monoclonal Paraproteinemia Disease

Therapeutic assets addressing Monoclonal Paraproteinemia Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lenalidomide Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P3	BB (65)
Dexasone Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	B (60)
Pomalidomide Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	B (60)
Bortezomib Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	CCC (53)
Cyclophosphamide Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	CCC (53)
Isatuximab Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	CCC (53)
Ranitidine Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	CCC (53)
Diphenhydramine Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P2	CCC (51)
Belantamab Mafodotin Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P1/2	CC (47)
Daratumumab Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P1/2	CC (47)
Nirogacestat Monoclonal Paraproteinemia Disease	Hellenic Society of Hematology	P1/2	CC (45)
Kln-1010 Monoclonal Paraproteinemia Disease	Kelonia Therapeutics, Inc.	P1	CC (43)
Oricar-017 Monoclonal Paraproteinemia Disease	OriCell Therapeutics Co., Ltd.	P1	CC (43)